NOV 25, 2018 7:26 PM PST

Advancing Drug Therapies for an Increasing Case of a Parasitic infection Among Displaced Syrians

WRITTEN BY: Nouran Amin

Cases of Cutaneous leishmaniasis (CL), a parasitic disease, has increased dramatically in Syria and neighboring countries as a result of the conflict-related displacement of Syrians.

Drawing depicting family feeling war-torn Syria.

Credit: Jan Birck via Public International Radio (PRI.org)

Now, a recent study published in PLOS Neglected Tropical Diseases by Rana El Hajj at the American University of Beirut, Lebanon describes the development of a novel immunomodulatory analog that will seek to advance the treatment of CL.

Cutaneous leishmaniasis (CL) is a parasitic infection with occurrences throughout the Americas from Texas to Argentina, and in the Old World, particularly the Middle East and North Africa. The infection is spread via by a female sandfly and is diagnosed annually in travelers, immigrants, and military personnel. Health care providers in the United States must alert to the diagnosis of leishmaniasis in travelers flying from endemic areas.

Presently, current therapeutics for CL can induce partial or complete cure. But these therapies come with multiple limitations, such as repetitive painful administrations, lack of availability, increased cost, and the emergence of resistant strains. Most importantly, the efficacy of these therapies are effected by the patient's age and immune system.

Learn more about Cutaneous leishmaniasis (CL):

In the study, the pre-clinical efficacy of the immunomodulatory drug--Imiquimod and one of its analogs, EAPB0503--on two strains (Leishmania major and Leishmania tropica) were investigated. These strains are known to cause CL in regions of the Middle East. These drugs were also tested on freshly isolated parasites from biopsies that proved their leishmanicidal potency.

The authors note, "Our findings establish Imiquimod as a strong candidate for treating L. tropica and show the higher potency of its analog EAPB0503 against CL."

The study is a promising solution to a current global health crisis and will effectively combat the increasing cases of CL.

Source: American Family Physician, PLOS Neglected Tropical Diseases

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
New Painkiller More Effective than Opioids Discovered in Mud
Researchers have discovered a new painkiller dubbed to be as effective as opioids, only minus their disadvantages, from a 16-year old mud sample found near...
DEC 08, 2019
Drug Discovery & Development
DEC 08, 2019
Parkinson's Drug Reduces Hallucinations in Dementia Patients
Pimavanserin, also known as Nuplazid, was approved in the US to treat Parkinson’s-related psychosis in 2016. Now, new research has shown that it also...
DEC 11, 2019
Drug Discovery & Development
DEC 11, 2019
Drug Candidates for Alzheimer Disease May Reverse Effects of Aging
Researchers using mouse models of Alzheimer disease were able to demonstrate that the investigational drug candidates ‘CMS121’ and ‘J147&...
DEC 25, 2019
Drug Discovery & Development
DEC 25, 2019
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
JAN 15, 2020
Cancer
JAN 15, 2020
Hope for patients with AML
Research published recently in the medical journal EMBO Molecular Medicine brings hope for leukemia patients with a report that a common and cheap drug may...
JAN 20, 2020
Cell & Molecular Biology
JAN 20, 2020
Using Modified Red Blood Cells As a Drug Delivery System
For a drug to be effective, it has to get to the right place to exert its impact....
Loading Comments...